Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Laszlo Mark, György Paragh & Kausik K. Ray. (2017) The need for a new classification of cholesterol lowering therapies. Current Medical Research and Opinion 33:1, pages 67-69.
Read now
Read now
Dujrudee Chinwong, Jayanton Patumanond, Surarong Chinwong, Khanchai Siriwattana, Siriluck Gunaparn, John Joseph Hall & Arintaya Phrommintikul. (2015) Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand. Therapeutics and Clinical Risk Management 11, pages 659-667.
Read now
Read now
Dujrudee Chinwong, Jayanton Patumanond, Surarong Chinwong, Khanchai Siriwattana, Siriluck Gunaparn, John Joseph Hall & Arintaya Phrommintikul. (2015) Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. Therapeutics and Clinical Risk Management 11, pages 127-136.
Read now
Read now
Furio Colivicchi, Catarina Sternhufvud & Sanjay K Gandhi. (2015) Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. ClinicoEconomics and Outcomes Research 7, pages 555-565.
Read now
Read now
Vasilios G. Athyros, Niki Katsiki & Manfredi Rizzo. (2014) Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Current Medical Research and Opinion 30:12, pages 2425-2428.
Read now
Read now
Christos V. Rizos, Fotios Barkas & Moses S. Elisaf. (2014) Reaching low density lipoprotein cholesterol targets. Current Medical Research and Opinion 30:10, pages 1967-1969.
Read now
Read now
Ayman J. Hammoudeh, Akram Echtay, Georges Y. Ghanem & Jihad Haddad. (2014) Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Current Medical Research and Opinion 30:10, pages 1957-1965.
Read now
Read now
Jung Ah Lee, Sung Sunwoo, Young Sik Kim, Han Jin Oh, Hee-Cheol Kang, Kyung-Chae Park, Dong Hyuk Sin, Sang Yeoup Lee, Yun Jun Yang, Byung Yeon Yu & Chul-Min Kim. (2013) Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care. Current Medical Research and Opinion 29:7, pages 751-760.
Read now
Read now
Laszlo Mark, György Paragh & Istvan Reiber. (2011) The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient. Current Medical Research and Opinion 27:10, pages 1959-1960.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Read now
Loukianos S Rallidis, Christos Kotakos, Vassilios Sourides, Christos Varounis, Athanasios Charalampopoulos, Maria Zolindaki, Nikolaos Dagres, Costas Papadopoulos & Maria Anastasiou-Nana. (2011) Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Expert Opinion on Pharmacotherapy 12:10, pages 1481-1489.
Read now
Read now
Michel P Hermans & Jean-Charles Fruchart. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. Clinical Lipidology 5:6, pages 811-826.
Read now
Read now
Stella S. Daskalopoulou, Robert J. Doonan & Dimitri P. Mikhailidis. (2010) Undertreatment of hypercholesterolemia. Current Medical Research and Opinion 26:2, pages 439-443.
Read now
Read now
Articles from other publishers (40)
Najiao Hong, Yongjun Lin, Zhirong Ye, Chunbaixue Yang, Yulong Huang, Qi Duan & Sixin Xie. (2022) The relationship between dyslipidemia and inflammation among adults in east coast China: A cross-sectional study. Frontiers in Immunology 13.
Crossref
Crossref
Ashish Sarraju, Andrew Ward, Jiang Li, Areli Valencia, Latha Palaniappan, David Scheinker & Fatima Rodriguez. (2022) Personalizing cholesterol treatment recommendations for primary cardiovascular disease prevention. Scientific Reports 12:1.
Crossref
Crossref
Jean Ferrieres, Gaetano Maria De Ferrari, Michel P. Hermans, Moses Elisaf, Peter P. Toth, Martin Horack, Philippe Brudi, Dominik Lautsch, Lori D. Bash, Carl A. Baxter, Veronica Ashton, Baishali Ambegaonkar & Anselm K. Gitt. (2018) Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. European Journal of Preventive Cardiology 25:18, pages 1966-1976.
Crossref
Crossref
Gaetano M. De Ferrari, Gian P. Perna, Antonino Nicosia, Luigina Guasti, Gavino Casu, Claudio Cuccia, Francesca Picco, Caterina Strazzella, Rossana Totaro, Stefania Cercone, Laura Canullo, Martin Horack, Dominik Lautsch, Anselm K. Gitt & Matteo Di Biase. (2018) Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. Journal of Cardiovascular Medicine 19:9, pages 485-490.
Crossref
Crossref
Nicolas Danchin, Wael Almahmeed, Khalid Al-Rasadi, Joseph Azuri, Abdelkrim Berrah, Carlos Alberto Cuneo, Yuri Karpov, Upendra Kaul, Meral Kayıkçıoğlu, Olena Mitchenko, Alvaro J Ruiz, Carlos A Aguilar Salinas, Raul D Santos, Florence Mercier & Dirk Blom. (2018) Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European Journal of Preventive Cardiology 25:10, pages 1087-1094.
Crossref
Crossref
Guy G De Backer. (2018) Prevention of cardiovascular disease: Much more is needed. European Journal of Preventive Cardiology 25:10, pages 1083-1086.
Crossref
Crossref
Sergey Boytsov, Natalia Logunova, Yunona Khomitskaya, Eradzh Nuraliev, Anastasiya Lebedeva, Inessa Shchelkunova, Elena Vershuta, Svetlana Zhidkova, Veronika Rostorotskaya, Yana Shadaniya, Andrey Ivanov, Irina Zobenko, Olga Kvasova, Svetlana Zikun, Alina Glushchenya, Alexander Rumyantsev, Svetlana Prokof’eva, Mariya Baturova, Rodion Oseshnyk, Elena Zhukova, Irina Shumikhina, Vera Eltisheva, Larisa Bugaets, Vladimir Chernysh, Marina Ivochkina, Lyudmila Svistunova, Natalia Klimenko, Olga Kulchitskaya, Valentina Alexandrova, Marina Stepanova, Tatiana Chernysh, Galina Ivanchura, Olga Chachshina, Elena Afonina, Andrey Chernyshev, Evgeniya Korostyleva, Tatyana Staroverova, Yuriy Badin, Galina Il’icheva, Lyudmila Monetkina, Oxana Novikova, Olga Abashina, Galina Plaksina, Svetlana Kostomarova, Ekaterina Alieva, Olga Budanova, Inessa Kartashova, Svetlana Chepurnenko, Elena Oreshina, Natalia Skachkova, Rkiya Khanbekova, Olga Pashchenko, Yuliya Zolotova, Elena Volodina, Konstantin Fisher, Anastasiya Shurkevich, Elena Vikhman, Irina Poshinova, Vladislav Abramov, Daniil Cherepnin, Olga Leonova, Olga Kargina, Galina Gerent, Natalia Nabokikh, Galina Sokolovskikh, Valeria Tkhorikova, Lyudmila Titova, Svetlana Rachkova, Andrey Baglikov, Marinsa Giorgadze, Alexander Malygin, Svetlana Strelkova, Tatyana Ryzhova, Nina Kochladze, Natalia Vyasova, Sergey Vasiliev, Inna Bondarenko, Elena Mokhnacheva, Lyudmila Shumilina & Svetlana Pakhomova. (2017) Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II). Cardiovascular Diabetology 16:1.
Crossref
Crossref
Fanny Lepeytre, Héloise Cardinal, Lorraine Fradette, Jacobien Verhave, Marc Dorais, Jacques LeLorier, Vincent Pichette & François Madore. (2017) The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients. Clinical Kidney Journal 10:3, pages 375-380.
Crossref
Crossref
Ashraf Reda, Alaa Etman, Ali Abdel-Rahim, Nabil Farag, Osama Sanad & Sameh Salamah. (2017) Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. Cardiology and Therapy 6:1, pages 105-120.
Crossref
Crossref
Yuriy Sirenko & Ganna Radchenko. (2017) Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High Blood Pressure & Cardiovascular Prevention 24:1, pages 85-93.
Crossref
Crossref
Terry McCormack, Ricardo Dent & Mark Blagden. (2016) Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. International Journal of Clinical Practice 70:11, pages 886-897.
Crossref
Crossref
Amirhossein Sahebkar, Maria-Corina Serban, Anna Gluba-Brzózka, Dimitri P. Mikhailidis, Arrigo F. Cicero, Jacek Rysz & Maciej Banach. (2016) Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition 32:11-12, pages 1179-1192.
Crossref
Crossref
Naomi J Rankin, David Preiss, Paul Welsh & Naveed Sattar. (2016) Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future: Table 1.. International Journal of Epidemiology 45:5, pages 1351-1371.
Crossref
Crossref
Deborah F. van Breukelen-van der Stoep, Derkjen van Zeben, Boudewijn Klop, Gert-Jan M. van de Geijn, Hans J. W. Janssen, Noelle van der Meulen, Marijke A. De Vries, Mieke Hazes, Erwin Birnie & Manuel Castro Cabezas. (2016) Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology 55:7, pages 1210-1216.
Crossref
Crossref
Chern-En Chiang, Jean Ferrières, Nina N Gotcheva, Frederick J Raal, Abdulla Shehab, Jidong Sung, Karin M Henriksson & Michel P Hermans. (2016) Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). Journal of Atherosclerosis and Thrombosis 23:5, pages 567-587.
Crossref
Crossref
Mei Liu, Xianying Su, Guofei Li, Guilian Zhao & Limei Zhao. (2015) Validated UPLC–MS/MS method for simultaneous determination of simvastatin, simvastatin hydroxy acid and berberine in rat plasma: Application to the drug–drug pharmacokinetic interaction study of simvastatin combined with berberine after oral administration in rats. Journal of Chromatography B 1006, pages 8-15.
Crossref
Crossref
Kornelia Kotseva. (2015) Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice—Can We Do Better?. Current Treatment Options in Cardiovascular Medicine 17:12.
Crossref
Crossref
P. Antiochos, P. Marques-Vidal, G. Waeber & P. Vollenweider. (2015) Five year trends in dyslipidaemia prevalence and management in Switzerland: The CoLaus study. Nutrition, Metabolism and Cardiovascular Diseases 25:11, pages 1007-1015.
Crossref
Crossref
S. Asgary, A. Sahebkar & N. Goli-malekabadi. (2015) Ameliorative effects of Nigella sativa on dyslipidemia. Journal of Endocrinological Investigation 38:10, pages 1039-1046.
Crossref
Crossref
Arinze Nkemdirim Okere & Courtney Serra. (2015) Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:8, pages 771-779.
Crossref
Crossref
Christopher P. Cannon, Bertrand Cariou, Dirk Blom, James M. McKenney, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari & Helen M. Colhoun. (2015) Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European Heart Journal 36:19, pages 1186-1194.
Crossref
Crossref
Hernán N. Lemus & Carlos O. Mendivil. (2015) Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia. Journal of Clinical Lipidology 9:3, pages 384-389.
Crossref
Crossref
Helen M Colhoun, Jennifer G Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J Kereiakes, Christelle Lorenzato, Robert Pordy & Umesh Chaudhari. (2014) Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders 14:1.
Crossref
Crossref
A. Reda, A. A. Abdel-Rehim, A. Etman & O. S. A. Afifi. (2014) Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt. Cardiology and Therapy 3:1-2, pages 27-40.
Crossref
Crossref
Mohamed Arafah, Ali T. Al-Hinai, Wael Al Mahmeed, Khalid Al-Rasadi, Omer Al Tamimi, Shorook Al Herz, Faisal Al Anazi, Khalid Al Nemer, Othman Metwally, Akram Alkhadra, Mohammed Fakhry, Hossam Elghetany, Abdel Razak Medani, Afzal Hussein Yusufali, Obaid Al Jassim, Omar Al Hallaq, Fahad Omar Ahmed S. Baslaib, Mahmoud Alawadhi, Haitham Amin, Khamis Al-Hashmi & Abdullah Shehab. (2013) Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia. Angiology 65:10, pages 919-926.
Crossref
Crossref
Soumaïla Camara, Evariste Bouenizabila, Michel P. Hermans, Sylvie A. Ahn & Michel F. Rousseau. (2014) Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8:3, pages 145-151.
Crossref
Crossref
Ko-Fan Wang, Chun-Chin Chang, Kang-Ling Wang, Cheng-Hsueh Wu, Lung-Ching Chen, Tse-Min Lu, Shing-Jong Lin & Chern-En Chiang. (2014) Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. Journal of the Chinese Medical Association 77:2, pages 61-67.
Crossref
Crossref
Kang-Ling Wang, Cheng-Hsueh Wu, Ko-Fan Wang, Chun-Chin Chang, Lung-Ching Chen, Tse-Min Lu, Shing-Jong Lin & Chern-En Chiang. (2014) The Association between Low-Density Lipoprotein Cholesterol Goal Attainment, Physician and Patient Attitudes and Perceptions, and Healthcare Policy. Journal of Atherosclerosis and Thrombosis 21:10, pages 1044-1054.
Crossref
Crossref
Jidong Sung, Sang Hyun Kim, Hye Ryoung Song, Myung Hwan Chi & Jeong Euy Park. (2014) Lipid-Lowering Treatment Practice Patterns in Korea: Comparison with the Data Obtained from the CEPHEUS Pan-Asian Study. Journal of Atherosclerosis and Thrombosis 21:11, pages 1219-1227.
Crossref
Crossref
Michel P Hermans, Carlos Brotons, Moses Elisaf, Georges Michel, Erik Muls & Frank Nobels. (2012) Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. European Journal of Preventive Cardiology 20:6, pages 1095-1105.
Crossref
Crossref
S. A. Boytsov & Yu. V. Khomitskaya. (2013) CENTRALISED SURVEY ON THE UNDERTREATMENT OF THE HYPERCHOLESTEROLEMIA IN RUSSIA (CEPHEUS). Cardiovascular Therapy and Prevention 12:4, pages 67-74.
Crossref
Crossref
Laurent Querton, Martin Buysschaert & Michel P. Hermans. (2012) Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. Journal of Clinical Lipidology 6:5, pages 434-442.
Crossref
Crossref
Loukianos S. Rallidis, Katerina Fountoulaki & Maria Anastasiou-Nana. (2012) Managing the underestimated risk of statin-associated myopathy. International Journal of Cardiology 159:3, pages 169-176.
Crossref
Crossref
Jeong Euy ParkChern-En ChiangMuhammad MunawarGia Khai PhamApichard SukonthasarnAnastacio R AquinoKah Lin KhooHon Wah Raymond Chan. (2011) Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. European Journal of Preventive Cardiology 19:4, pages 781-794.
Crossref
Crossref
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Crossref
Evangelos Liberopoulos, Fotini Vlasserou, Zoe Mitrogianni, Ioannis Papageorgantas & Moses Elisaf. (2011) Prevalence and Risk Distribution of Residual Dyslipidemia in Statin-Treated Patients in Greece. Angiology 63:3, pages 184-193.
Crossref
Crossref
Michel P. Hermans & Jean-Charles Fruchart. (2011) Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Therapeutic Advances in Chronic Disease 2:5, pages 307-323.
Crossref
Crossref
M. C. S. Wong, J. Y. Jiang & S. M. Griffiths. (2011) Adherence to lipid-lowering agents among 11,042 patients in clinical practice. International Journal of Clinical Practice 65:7, pages 741-748.
Crossref
Crossref
Pia Kirkegaard, Adrian GK Edwards, Bo Hansen, Mette D Hansen, Morten SA Jensen, Torsten Lauritzen, Mette B Risoer & Janus L Thomsen. (2010) The RISAP-study: a complex intervention in risk communication and shared decision-making in general practice. BMC Family Practice 11:1.
Crossref
Crossref
Mathieu Firmann, Pedro Marques-Vidal, Fred Paccaud, Vincent Mooser, Nicolas Rodondi, Gérard Waeber & Peter Vollenweider. (2010) Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. European Journal of Cardiovascular Prevention & Rehabilitation 17:6, pages 682-687.
Crossref
Crossref